Clinical Trials in Miami

Showing 1041-1060 of 5,521 trials

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

NCT07221227

The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.

Non-alcoholic Fatty Liver Disease

GlaxoSmithKline1,200 participantsStarted Oct 2025

Miami, Florida, United States

Active Not RecruitingPhase 2< 1 mile

SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST

NCT06208748

This is an open label, single arm, phase 2 trial investigating bezuclastinib plus sunitinib in patients with GIST who have previously progressed on sunitinib.

Gastrointestinal Stromal TumorsGIST

Sarcoma Alliance for Research through Collaboration40 participantsStarted Aug 2024

Miami, Florida, United States • Boston, Massachusetts, United States • Portland, Oregon, United States +1 more locations

Active Not RecruitingPhase 2< 1 mile

A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

NCT06335173

The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.

Alzheimer Disease

Acumen Pharmaceuticals542 participantsStarted Feb 2024

Carlsbad, California, United States • Fullerton, California, United States • Irvine, California, United States +65 more locations

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST

A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

Find Trials by Condition in Miami

Phase 2b Study of GSK4532990 in Adults With NASH

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).

A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema

Digital Detection of Dementia (D Cubed) Studies: D3

To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate

FebriDx® Pediatric Validation Study

ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD

A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

Safety and Effectiveness Study of OR3O™ Dual Mobility System in THA

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia

Integration of Hypertension Management Into HIV Care in Nigeria

Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)